Mortgage Marketshare Module
- Accurately track commercial and residential lending, measure sales performance against competition and market activity, identify high-performing competitors, and locate and target emerging markets.
  
  LEARN MORE >>
Loan Originator Module
- Access the largest and most comprehensive mortgage loan origination database in New England with round-the-clock interactive access and weekly trend updates.
  
  LEARN MORE >>
Marketing Lists
- Gain access to the most accurate and detailed transaction information in the country and offers a range of marketing lists for more than 130 million households (covering 94% of the U.S. population).
  
  LEARN MORE >>
Custom Research
- Powered by one-of-a-kind real estate, mortgage, and loan origination data, The Warren Group provides custom solutions for your research projects, database expansion, and strategic planning.
  
  LEARN MORE >>
Real Estate Records Search
- Access the largest and most complete real estate database in New England, including sales, price trends, liens and foreclosures.
  
  LEARN MORE >>

Swedish Biotech Opens Waltham Headquarters

Jun 16, 2014 | Reprints | Print

Swedish biotech company Sobi opens its North American headquarters at 890 Winter St. in Waltham today.

Rami Levin, Sobi’s vice president for North America, said the company chose Waltham because of Massachusetts’s biotech cluster and strong talent pool.

"This also offers us the opportunity to collaborate with some of the finest research institutions and universities in the world," Levin said in a statement.

The Stockholm-based company opened its first U.S. affiliate in 2012 in Pennsylvania. The Massachusetts Life Sciences Center worked with the company on its relocation plans. Sobi will have 21 employees in the 8,000-square-foot office by year’s end, according to the life sciences center.

Sobi specializes in protein biochemistry and biologics manufacturing. In the North American market, the company focuses on inflammatory, genetic and metabolic diseases. Its Orfadin drug is FDA-approved for treatment of Type 1 tyrosinaemia, which causes liver and kidney diseases.

NULL